OCV
VC Fund
Los Angeles, United States
OCV is a VC fund in Los Angeles focused on Biotechnology and Health Care. OCV Management LLC is a Los Angeles based investment adviser co-founded by Richard Ressler and Mark Yung in 2016. The firm leverages an investment strategy deployed successfully since 1993 and a team of seasoned professionals who have worked together for an average of 19 years. OCV invests in companies with differentiated technologies andcompelling target markets, with the objective of assisting companies create sustainable long-term value. As partners, OCV provides operational and financial expertise through its experienced principals, who have proven success as entrepreneurs, business leaders and investors across a variety of sectors including technology, healthcare, industrials, real estate and finance. OCV invests across all stages of a company’s growth cycle, and finds creative investment solutions to fit a company’s needs. For more information, visit http://www.ocvpartners.com.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $200M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries OCV invests in
Stages OCV invests in
Countries OCV invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Series A
- $13M–$70M
- Series B
- $50M–$158M
- Series C
- $10M–$110M
Investment Focus
Industry
- Biotechnology 6 (23%)
- Health Care 5 (19%)
- Software 4 (15%)
- Artificial Intelligence 3 (12%)
- Medical 2 (8%)
Stage
- Series A 7 (27%)
- Series C 6 (23%)
- Series B 5 (19%)
- Series D 2 (8%)
- Seed 1 (4%)
Country
- United States 12 (46%)
- Israel 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chris Bostick
Partner
|
Partner | Total investments: 0 | Find email | |
Hemi Zucker
Managing Partner
|
Managing Partner | Total investments: 8 | Find email | |
Zohar Loshitzer
General Partner
|
General Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Orca AI
|
Founded in 2018 by a team of Navy veterans, Orca AI, a maritime tech startup, empowers shipping companies to enhance their operational safety, efficiency, and sustainability through a single AI and computer-vision-based operations platform. By October 2024, 900 vessels have been booked, and 550 installations have already been completed. Theplatform is trusted by key industry players across various shipping segments, including MSC, Seaspan, Maran Tankers / Angelicoussis Group, NYK, and Marubeni. The company has raised a total of $38 million in funding over two rounds from US, UK, and Israeli VCs and employs 80 people across its offices in London, Athens, Singapore, and Tel Aviv. | $72.5M / Series B / May 06, 2025 | |
|
Orca AI
|
Founded in 2018 by a team of Navy veterans, Orca AI, a maritime tech startup, empowers shipping companies to enhance their operational safety, efficiency, and sustainability through a single AI and computer-vision-based operations platform. By October 2024, 900 vessels have been booked, and 550 installations have already been completed. Theplatform is trusted by key industry players across various shipping segments, including MSC, Seaspan, Maran Tankers / Angelicoussis Group, NYK, and Marubeni. The company has raised a total of $38 million in funding over two rounds from US, UK, and Israeli VCs and employs 80 people across its offices in London, Athens, Singapore, and Tel Aviv. | $72.5M / Series B / May 06, 2025 | |
Rad AI
|
Rad AI develops an artificial intelligence automated report generation platform to automate repetitive tasks for radiologists. Its platform integrates with existing workflow, automating repetitive tasks, and enabling radiologists to improve radiology workflow that maximizes efficiency and accuracy while reducing burnout for radiologists andimproving patient care. | $60M / Series C / Jan 25, 2025 | |
Ossio
|
OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents abreakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now. | $27.6M / Series D / Dec 02, 2024 | |
|
Orca AI
|
Founded in 2018 by a team of Navy veterans, Orca AI, a maritime tech startup, empowers shipping companies to enhance their operational safety, efficiency, and sustainability through a single AI and computer-vision-based operations platform. By October 2024, 900 vessels have been booked, and 550 installations have already been completed. Theplatform is trusted by key industry players across various shipping segments, including MSC, Seaspan, Maran Tankers / Angelicoussis Group, NYK, and Marubeni. The company has raised a total of $38 million in funding over two rounds from US, UK, and Israeli VCs and employs 80 people across its offices in London, Athens, Singapore, and Tel Aviv. | $23M / Venture - Series Unknown / May 23, 2024 | |
|
Orca AI
|
Founded in 2018 by a team of Navy veterans, Orca AI, a maritime tech startup, empowers shipping companies to enhance their operational safety, efficiency, and sustainability through a single AI and computer-vision-based operations platform. By October 2024, 900 vessels have been booked, and 550 installations have already been completed. Theplatform is trusted by key industry players across various shipping segments, including MSC, Seaspan, Maran Tankers / Angelicoussis Group, NYK, and Marubeni. The company has raised a total of $38 million in funding over two rounds from US, UK, and Israeli VCs and employs 80 people across its offices in London, Athens, Singapore, and Tel Aviv. | $23M / Venture - Series Unknown / May 23, 2024 | |
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M / May 13, 2024 | |
|
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M / Series C / May 13, 2024 | |
|
Rad AI
|
Rad AI develops an artificial intelligence automated report generation platform to automate repetitive tasks for radiologists. Its platform integrates with existing workflow, automating repetitive tasks, and enabling radiologists to improve radiology workflow that maximizes efficiency and accuracy while reducing burnout for radiologists andimproving patient care. | $50M / Series B / May 07, 2024 | |
TORL BioTherapeutics
|
TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs. | $158M / Series B / Apr 13, 2023 | |
| See all 26 investments → | |||
Co-Investors
MizMaa Ventures
9 deals together
Bellco Capital
6 deals together
Gaingels
5 deals together
Playfair Capital
5 deals together
Ankona Capital Partners
4 deals together
Brighton Park Capital
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does OCV invest in?
OCV invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Series C stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is OCV's check size?
OCV typically joins rounds of $13M–$70M at Series A, $50M–$158M at Series B and $10M–$110M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds OCV participates in.
How do I contact OCV?
Public channels for OCV include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at OCV?
The team at OCV includes Chris Bostick (Partner), Hemi Zucker (Managing Partner) and Zohar Loshitzer (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
